Research on Seladelpar in treating primary biliary cholangitis (PBC) highlights its potential as an alternative or complementary therapy to existing treatments like ursodeoxycholic acid and obeticholic acid. These medications are used to manage PBC by improving liver function and reducing bile buildup.
The focus on Seladelpar suggests an interest in exploring new treatment options for managing PBC symptoms and slowing disease progression. This study could provide insights into how Seladelpar compares to current therapies in terms of efficacy and patient outcomes, contributing to the search for effective treatments for PBC, a condition with limited therapeutic options beyond current medications and liver transplantation in advanced cases Study (2025).
Clinical Trials
This is a list of upcoming or ongoing clinical trials that are actively recruiting and have been listed or updated in the last two weeks:
